Takis

At Takis, we offer expert flow cytometry services for rapid, multi-parametric analysis of single cells in solution. Our team specialized in this service, providing up to 20-parameter analyses with both custom and ready-to-use panels. We work with a variety of sample types, including blood cells, tumors, and cell lines, offering services like cellular phenotyping, proliferation studies, apoptosis analysis, and more. From assay design to data reporting, we ensure precise and reliable results. Check out this carousel to find out about our flow cytometry services and contact us on LinkedIn to learn more!

Meet Lucia Lione, biotechnologist and researcher at Takis! Lucia joined Takis first through an industrial PhD program in oncology, in which she focused on studying the interactions between DNA-based vaccines against tumor antigen delivery by electroporation, immune response, and microbiota. After the PhD, she remained at Takis, where she extended her expertise in tumor immunology, assessing the efficacy of cancer vaccines. During the pandemic, she has also contributed to evaluating the efficacy of the COVID-eVax during preclinical studies. She is currently conducting preclinical studies testing antitumoral vaccines, both alone and in combination with conventional immunotherapies, to evaluate their antitumor efficacy. She’s involved in the FIDIA project, which aims to establish a cGMP facility for the production of genetic vaccines, particularly a completely synthetic linear DNA vaccine. We thank Lucia and every member of the team for their hard work! Want to know more about Takis projects and studies? Contact us here on LinkedIn!

A new cellular #immunotherapy approach may be effective in treating metastatic solid #tumors! An important finding this July has been made by the National Institutes of Health, which reported early findings from a clinical trial. In the experiment, researchers from the National Institutes of Health (NIH) genetically engineered normal lymphocytes from each patient to produce receptors that recognize and attack their specific cancer cells. According to Steven A. Rosenberg, M.D., Ph.D., of NCI’s Center for Cancer Research (CCR): “the fact that we can take a growing metastatic solid cancer and get it to regress shows that the new cellular immunotherapy approach has promise. However, it’s important to understand that these findings are preliminary and that the approach needs to be further refined and tested.” As Takis, we are focused on every step Immunotherapy takes in science to propose new solutions and progress with our research and services. We are committed to develop our own immunotherapy products as well as support other Pharma companies that want to test new immunotherapies with our in vitro and in vivo models. If you want to know more about our services on Immunotherapy please contact us here on LinkedIn!

Even in August, #Research Doesn't Stop! Unfortunately, diseases never go on vacation, so we are proud to work even during the summer months, with passion and dedication. At Takis, after a few days off, we are ready again to start new projects and work for our clients. Committed to the research and development of new therapies, we are continuing to explore new scientific frontiers and make significant advances in immunotherapies, offering custom solutions and services that yield reliable and replicable results. A big thank you goes to our entire team for their dedication and passion even during #August. Takis’ team is the engine that always drives us forward.

We know that flexibility in research and experiments is fundamental to evaluating the effectiveness of new drugs. Not all models can be simply replicated! At Takis, we pride ourselves on our extensive experience and global reach, serving clients internationally with a diverse range of high-quality rodent models. For a model organism to be truly valuable, it must accurately replicate the normal anatomy and physiology of the human organs and tissues being studied. Additionally, it should reflect the morphological and biochemical aspects of disease pathogenesis. Takis offers comprehensive support across various stages of research, depicted in our detailed process chart. Clients have the flexibility to choose specific stages according to their research needs, ensuring a tailored approach that aligns with their goals and objectives. We specialize in both in vitro and in vivo immunotherapy drug testing, providing a robust platform for evaluating the efficacy and safety of new therapies. At Takis, we are committed to advancing biomedical research by providing top-notch animal models and expert guidance. Contact us to learn more about our services to achieve your scientific goals.

CAR-T cells increasingly demonstrate their potential by bringing surprising results even in immunoreumatological diseases. These are the conclusions reached by Professor Georg Schett in Erlangen on adults and Professor Franco Locatelli in Rome on pediatric patients, reported in this article by "Il Sole 24 Ore." Professor Georg Schett's insight is that CAR-T cells, which target the CD19 antigen, would be able to eliminate the autoreactive lymphocyte B cells associated with autoimmune diseases. The application scope of CAR-T cells, therefore, is thought to transcend the ones related to the treatment of leukemia, lymphoma and myeloma, to extend to autoimmune diseases, creating new possibilities toward the treatment of severe and severely disabling autoimmune diseases. At Takis, the study of CAR-T cells is therefore increasingly important for the new frontiers of medicine. We can help our clients test CAR-T cells on our mice models. Contact us here on LinkedIn if you want to realize an experiment using Car-T cells. We are ready to help! Here is the link to the article: https://lnkd.in/d5dW44eu

What's better than an “aperitivo” on the beach to celebrate the start of the #summer holidays? 😎 At Takis, we will continue to be open during August, delivering our services without interruption. However, we know that in Italy many take their holidays during August, including members of our staff of course, so we wanted to spend a moment together to wish everyone good holidays. It was a great opportunity to thank our #team members for their continued commitment and to celebrate together the successes we have achieved so far this year. We wish everyone great summer #holidays, filled with rest and fun. We look forward to coming back full of energy to face new challenges and achieve more goals together!

Takis’s employees recently participated in a LinkedIn training session with Marco Scuri, Founder of SPEM and Marketing & LinkedIn Expert. This workshop was an excellent opportunity for our team to deepen our knowledge on #LinkedIn, learning new strategies on how to optimize profiles, post content, expand our professional #network and improve our digital presence. We thank Marco for sharing his expertise and providing us with valuable tools to better navigate this essential platform for networking and #marketing. We are excited to apply this knowledge on this platform! Follow us to see our journey.

#Immunotherapy is at the core of everything we do at Takis. This type of therapy now is used to treat several #cancer types, activating the immune system in a more and more effective way. As Takis, we are committed to the field of immunotherapy, doing internal and funded #research in this field, collaborating with #public and #private institutions. We also help other #pharmaceutical companies to develop effective products, with a wide range of reliable in vitro and in vivo models to study different immunotherapies. This is still an experimental field, and if you want a reliable partner to test new immunotherapies and validate them, contact us here on LinkedIn to know more about our services.

At Takis, we know how crucial delivery #time is to the #success of our #projects and the satisfaction of our customers. That's why we pay close attention to this #KPI, ensuring not only punctuality, but also quality and reliability at every stage of our work. Thanks to a #team of highly qualified experts, we are able to deliver replicable and reliable results, meeting the highest scientific and technological standards. Our rigorous #methodology ensures that each project is completed with precision and attention to detail, meeting deadlines without ever compromising the quality of our work. In addition, our collaborative and transparent approach allows us to work closely with our #customers, ensuring constant and clear #communication throughout the process. At Takis, we strive to maintain our promises of reliable and replicable results within the shortest time frame possible. If you want to know more about our #services, send us a message here on LinkedIn! #pharma #research #pharmaceutical